Shine-On BioMedical Co.,Ltd.
Taipei Exchange 6926.TWO
Shine-On BioMedical Co.,Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -82.23
Shine-On BioMedical Co.,Ltd. Price to Earnings Ratio (P/E) is -82.23 on January 14, 2025, a -5.40% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
-
Shine-On BioMedical Co.,Ltd. 52-week high Price to Earnings Ratio (P/E) is -72.15 on August 06, 2024, which is 12.25% above the current Price to Earnings Ratio (P/E).
-
Shine-On BioMedical Co.,Ltd. 52-week low Price to Earnings Ratio (P/E) is -87.01 on October 30, 2024, which is -5.82% below the current Price to Earnings Ratio (P/E).
-
Shine-On BioMedical Co.,Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -79.47.
Key data
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
Market news
Loading...
Taipei Exchange: 6926.TWO
| CEO | Mr. Hongzhe Jiang |
| IPO Date | Nov. 25, 2022 |
| Location | |
| Headquarters | No. 633, Taiwan Avenue |
| Employees | 19 |
| Sector | Health Care |
| Industries | |
Description
Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. The company was founded in 2021 and is based in Taichung, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email